According to a recent LinkedIn post from Astraveus, the company plans to present its approach to CAR-T process development and manufacturing at the Advanced Therapies UK conference in London on March 17–18. The post highlights its Lakhesys™ microfluidic cell factory, described as a single system that covers the workflow from cell selection through expansion and harvest while aiming to reduce labor, reagent use, and infrastructure needs.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests that Astraveus views current CAR-T manufacturing as challenged more by economics than by scientific promise and is positioning Lakhesys™ as a potential answer to cost and scalability constraints. For investors, this emphasis on process efficiency and automation may indicate a strategy to capture value in the cell and gene therapy manufacturing segment, where lowering cost of goods and facility footprints is increasingly important for commercialization.
By engaging with a large gathering of pharma, biotech, CDMOs, clinicians, regulators, and start-ups, Astraveus appears to be seeking validation and early collaborators for user testing and process development. If such collaborations materialize, they could provide non-dilutive funding opportunities, de-risk technology adoption, and enhance the company’s visibility across the advanced therapy medicinal product value chain, potentially supporting longer-term partnership or exit prospects.